Your browser doesn't support javascript.
loading
Heparin and insulin in the management of acute hypertriglyceridemic pancreatitis / Heparina e insulina en el manejo de pancreatitis aguda asociada a hipertrigliceridemia
Camargo-Mendoza, Juan Pablo; Rodríguez-Ariza, Daniel Efrén; Bustos-Calvo, Jhonny Steven.
Affiliation
  • Camargo-Mendoza, Juan Pablo; Hospital de Kennedy. Unidad de Cuidado Intensivo. Bogotá. CO
  • Rodríguez-Ariza, Daniel Efrén; Hospital de Kennedy. Unidad de Cuidado Intensivo. Bogotá. CO
  • Bustos-Calvo, Jhonny Steven; Hospital de Kennedy. Bogotá. CO
Acta méd. colomb ; 45(1): 44-47, Jan.-Mar. 2020. tab, graf
Article in En | LILACS, COLNAL | ID: biblio-1124070
Responsible library: CO70
ABSTRACT
Abstract Hypertriglyceridemic pancreatitis (HTGP) is the third cause of acute pancreatitis in most studies, with a triglyceride (TG) risk value of more than 1000 mg/dL. The pathophysiological mechanism involves triglyceride hydrolysis by pancreatic lipase and the release of fatty acids which cause damage by producing free radicals. The reduction of TGs below 500 mg/dL is the treatment goal, based on increased lipoprotein lipase activity and chylomicron degradation. We present the case of a patient with HTGP with an adequate response to concomitant insulin and heparin therapy. (Acta Med Colomb 2020; 45. DOI https//doi.org/10.36104/amc.2020.1491).
RESUMEN
Resumen La pancreatitis secundaria a hipertrigliceridemia (PASHT) es la tercera causa de pancreatitis aguda en la mayoría de series, teniendo como factor de riesgo un valor de triglicéridos (TG) mayor a 1000 mg/dL. El mecanismo fisiopatológico involucra la hidrólisis de triglicéridos por la lipasa pancreática y la liberación de ácidos grasos que inducen el daño por la generación de radicales libres. La reducción de los TG a niveles menores de 500 mg/dL es el objetivo del tratamiento, basado en el aumento de la actividad de la lipoproteinlipasa y degradación de quilomicrones. Presentamos un caso de un paciente que presenta PASHT con adecuada respuesta al manejo concomitante de insulina y heparina.(Acta Med Colomb 2020; 45. DOIhttps//doi.org/10.36104/amc.2020.1491).
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: COLNAL / LILACS Main subject: Heparin / Insulin Type of study: Risk_factors_studies Limits: Adult / Humans Language: En Journal: Acta méd. colomb Journal subject: MEDICINA Year: 2020 Document type: Article Affiliation country: Colombia Country of publication: Colombia

Full text: 1 Collection: 01-internacional Database: COLNAL / LILACS Main subject: Heparin / Insulin Type of study: Risk_factors_studies Limits: Adult / Humans Language: En Journal: Acta méd. colomb Journal subject: MEDICINA Year: 2020 Document type: Article Affiliation country: Colombia Country of publication: Colombia